Sonabend Adam M, Ulasov Ilya V, Lesniak Maciej S
Division of Neurosurgery, The University of Chicago, Chicago, Illinois, USA.
Gene Ther Mol Biol. 2007;11(A):79-92.
High-grade gliomas remain relatively resistant to current therapy. Local recurrence is a common feature and the majority of patients progress despite conventional therapy. One modality-gene therapy-has shown a lot of promise in early preclinical and clinical studies aimed at advancing the treatment of this disease. In this review, we provide a comprehensive overview of clinical trials involving gene therapy in the field of neuro-oncology. The use of different delivery vehicles, including liposomes, cells, and viruses, as well genes, especially cytokines and suicide genes, are explored in detail. The unique features and advantages/disadvantages of the different vectors employed are compared based on results of human studies. We discuss both the limitations and successes encountered in these clinical trials, with an emphasis on the lessons learned and potential ways of improving current gene therapy protocols.
高级别胶质瘤对当前治疗仍相对耐药。局部复发是常见特征,尽管接受了传统治疗,大多数患者仍会病情进展。一种治疗方式——基因治疗——在旨在推进该疾病治疗的早期临床前和临床研究中已展现出很大前景。在本综述中,我们全面概述了神经肿瘤学领域涉及基因治疗的临床试验。详细探讨了不同递送载体的使用,包括脂质体、细胞和病毒,以及基因,特别是细胞因子和自杀基因。根据人体研究结果比较了所采用的不同载体的独特特征和优缺点。我们讨论了这些临床试验中遇到的局限性和成功之处,重点是吸取的经验教训以及改进当前基因治疗方案的潜在方法。